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any of three evaluated antibiotic. The use of resources as estimated according to 
Mexican Social Security Institutions expenses and its use were simulated within a 
decision tree with Bayesian approach. The model considered clinical success as the
best health state, reached in either short hospital stay or long hospital stay and a 
therapeutic failure of ﬁ rst-line antibiotic therapy (DAP, VAN or LIN) which caused 
the use of a second-line antibiotic therapy (DAP or LIN depending on ﬁ rst election). 
Costs calculation considered hospital stay, concomitant medication and selected anti-
biotic treatment. Results were evaluated with incremental analysis and one-way sen-
sitivity analysis of the most uncertain variables were also conducted. RESULTS: The
use of i.v. Daptomycin as ﬁ rst-line therapy followed by i.v. Linezolid in case of thera-
peutic failure resulted in the lowest total cost per clinical success (DAP-LIN: $3255.00 
USD/CS; VAN-DAP: $3310.00 USD/CS; VAN-LIN: $3310.00 USD/CS; LIN-DAP: 
$3423.00 USD), attaining a 98% of CS. The sensitivity analysis varying clinical success 
rates of every evaluated alternative showed robustness of base study. CONCLU-
SIONS: Daptomycin is the most cost-effective alternative in the treatment of CSSI 
when used as ﬁ rst-line antibiotic therapy since its use reduces the length of hospital 
stay reducing expenses of public health system budget in Mexico.
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OBJECTIVES: To determine the most cost-effective antibiotic treatment for compli-
cated skin and skin-structure infections (CSSI) in public health care institutions in 
Mexico. METHODS: A cost-effectiveness study with institutional perspective was 
conducted comparing the use of either i.v. Daptomycin (DAP), i.v. Vancomycin (VAN) 
or i.v. Linezolid (LIN) as ﬁ rst-line antibiotic therapy. Data collection obtained with a
systematic review considered efﬁ cacies measured as clinical improvement, length of 
stay at hospital services and adverse events. A decision tree with Bayesian approach
was designed to simulate the use of resources based on patient’s prognosis due to use 
one of the evaluated alternatives. Patients are supposed to reach either of two different 
health states: clinical success and therapeutic failure, the former can be attained 
through a short hospital stay or a long hospital stay depending on selected treatment, 
the latter requires the administration of a second-line antibiotic therapy increasing 
cost. Costs calculation considered hospital stay, concomitant medication and selected
antibiotic treatment. Results were evaluated with incremental analysis and one-way 
sensitivity analysis of the most uncertain variables were also conducted. RESULTS:
The use of i.v. Daptomycin results in the lowest total cost (DAP: $3,078.00 USD; 
VAN: $3,159.00 USD; LIN: $3,173.USD) and the lowest cost per clinical success (CS) 
(DAP: $3,405.00 USD/CS; VAN:$3,550.00 USD/CS; LIN:$3,870.00 USD/CS) com-
pared with i.v. Vancomycin or i.v. Linezolid. The sensitivity analysis varying clinical 
success rates of every evaluated alternative showed robustness of base study. CON-
CLUSIONS: Daptomycin is the most cost-effective alternative in the treatment of CSSI 
when used as ﬁ rst-line antibiotic therapy since its use reduces the length of hospital 
stay reducing expenses of public health system budget in Mexico.
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OBJECTIVES: Acute otitis media (AOM) is a prevalent pediatric condition, affecting
approximately 80% of children by three years of age. Routine immunization programs 
include 7-valent Pneumococcal conjugate vaccine (PCV-7), associated with a reduction
of AOM events caused by Streptococcus pneumoniae. The objective of this study was
to compare the costs and effects of PCV-7 with PHiD-CV, a newly approved in Canada
Pneumococcal non-typeable Haemophilus inﬂ uenzae Protein D-conjugate vaccine 
employing an active protein D-carrier associated with reduction of nontypeable Hae-
mophilus Inﬂ uenzae (NTHi) AOM. METHODS: A steady-state, population-based 
model with a one-year time horizon was developed, and calibrated with Canadian
epidemiologic and demographic data, to investigate the costs and effects associated 
with AOM episodes across the Canadian population. A 4-dose schedule for PHiD-CV 
vaccination was compared with a 4-dose schedule for PCV-7 vaccination. The base-
case included herd-protection for invasive pneumococcal disease and serotype 6A cross
protection. A health care system perspective was taken with the assumption of 100% 
vaccination coverage. RESULTS: Compared with PCV-7, vaccination with PHiD-CV 
could prevent an additional 170,951 ambulatory visits for AOM, 144,454 antibiotic 
prescriptions for AOM, and 9,830 hospitalizations for myringotomy per year. With 
PCV-7 the total direct costs associated with AOM are $119.8 million of which $16.9
million could be off-set by implementation of routine vaccination with PHiD-CV.
CONCLUSIONS: Based on the base-case analysis, inclusion of PHiD-CV in routine
immunization programs across Canada would be cost-saving to the health care system
compared with PCV-7. PHiD-CV offers substantial beneﬁ ts in terms of reduced ambu-
latory visits, antibiotic prescriptions and hospitalizations for AOM, a highly prevalent 
childhood condition.
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OBJECTIVES: Psoriasis is a chronic debilitating immune-mediated inﬂ ammatory
disease, with no cure, affecting an estimated one million Canadians. Studies show that
up to 85% of psoriasis is of plaque type and up to 25% of sufferers have either moder-
ate or severe disease. There are no reliable estimates of the economic burden of pso-
riasis in Canada. The objective is to estimate the economic burden of moderate to
severe chronic plaque psoriasis in Canada in 2008, inclusive of direct medical and
non-medical, and lost productivity costs. METHODS: Using a cross-sectional design, 
data were collected on 90 patients diagnosed with moderate or severe chronic plaque 
psoriasis in three dermatology clinics (British Columbia, Ontario, and Quebec). Data
were obtained from three sources: clinic charts determining medical resources utilized 
for treatment; patient questionnaires eliciting information on non-medical resources
utilized, lost productivity, and the impact on quality of life (QoL) using the Dermatol-
ogy Quality of Life Index (DLQI); and unit costs (all in CDN$2008) from published
sources. RESULTS: The estimated mean annual costs of treating patients with moder-
ate to severe chronic plaque psoriasis was $7966/patient, of which $4524 (95% con-
ﬁ dence interval (CI): $2246 to $6802) was due to direct medical and non-medical
costs, and $3442 (95% CI: $1293 to $5590) was due to lost productivity. The esti-
mated mean DLQI of 6.7 is reﬂ ective of a moderate impact on QoL in moderate to
severe psoriasis patients. CONCLUSIONS: Extrapolating these costs to the estimated 
number of affected Canadians means that moderate to severe psoriasis costs on the
order of $961.3 million (95% CI: $477.3 million to $1.4 billion) in direct medical 
and non-medical costs annually. The total cost to society is approximately $1.7 billion
(95% CI: $752.0 million to $2.6 billion). This economic burden coupled with the
QoL effect indicates the need for more efﬁ cient and long-term control.
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OBJECTIVES: Severe Chronic Hand Eczema (CHE) or Chronic Hand Dermatitis
(CHD), is characterized by thick scaly skin causing painful ﬁ ssures, erythema, itching, 
blustering and oedema. Severe CHE/CHD is often unresponsive to conventional 
topical corticosteroids and results in substantial occupational, personal, and psycho-
logical disability. There is currently a lack of information regarding the economic
burden of CHE/CHD in Canada. METHODS: A dynamic Excel model was devel-
oped to estimate the cost of treating adults with severe CHE in Canada. Epidemiologi-
cal/clinical data were derived from systematic literature searches. A Delphi panel of 
dermatologists provided estimates of resource utilization and validated epidemiologi-
cal/clinical rates. Given the impact on lost productivity, a pseudo societal perspective 
was chosen; out of pocket expenses (travel and non-prescription pharmacotherapies)
were excluded from the analysis. Unit costs were derived from Ontario standard lists
and reported as 2008 Canadian dollars. RESULTS: In 2008 the estimated adult popu-
lation was 26 million. From the literature it was determined that 10% of adults may 
be affected by CHE, of those 6.7% may have severe CHE/CHD. Asscessing 50% of 
these patients don’t adequately respond to topical corticosteroids, an estimated 87,200 
Canadians have severe CHE being refractory to topicals. Treatment costs, including 
lost productivity, was calculated to be $737 million per annum. Even assuming current 
second-line treatment options are 100% effective, the cost of severe CHE was esti-
mated to be $390 million per annum. CONCLUSIONS: This study estimated the costs 
of severe CHE/CHD unresponsive to topical corticosteroids in Canada ranges from 
$390–$737 million per annum. The majority of costs comes from lost productivity
due to disease and accessing treatment.
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OBJECTIVES: The purpose of this study was to assess the cost-utility of posterior
lamellar keratoplasty techniques, including deep lamellar endothelial keratoplasty 
(DLEK), Descemet stripping endothelial keratoplasty (DSEK) and Descemet stripping
automated endothelial keratoplasty (DSAEK), in the treatment of corneal endothelial 
diseases. METHODS: This cost-utility analysis was performed from a Canadian health
system perspective over a lifetime period. A Markov model was constructed to 
compare the cost per quality adjusted life year (QALY) associated to penetrating kera-
toplasty (PK) and lamellar keratoplasty techniques (DLEK, DSEK and DSAEK). The 
Markov model included all major health states relevant to patients scheduled for
corneal transplantation: waiting for transplantation, surviving graft with or without 
